Biotech company Biogen (NASDAQ:BIIB) beat Wall Street’s revenue expectations in Q2 CY2025, with sales up 7.3% year on year to ...

Shares of ImmunityBio (NASDAQ:IBRX) traded higher on Wednesday after the immunotherapy developer disclosed early-stage trial results for its natural killer cell therapy candidate in patients with a ...

Major indices were in the green early on Wednesday, with the S&P 500 and Nasdaq Composite building on yesterday's ...

Anavex faces dilution risk from its $150M ATM facility, high cash burn, and lack of revenue. Click here to see why AVXL stock ...